Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 17, 2014, 106 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $573.98 to $39,999,000.00.

Highlighted Stocks Traded by Insiders:

Fidelity National Information Services (FIS) - FREE Research Report

Woodall James W., who is Corporate EVP CFO at Fidelity National Information Services, sold 6,000 shares at $59.10 on Nov. 17, 2014. Following this transaction, the Corporate EVP CFO owned 60,973 shares meaning that the stake was reduced by 8.96% with the 6,000-share transaction.

The shares most recently traded at $59.81, up $0.71, or 1.18% since the insider transaction. Historical insider transactions for Fidelity National Information Services go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 22,900
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 22,900
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 22,900

The average volume for Fidelity National Information Services has been 1.2 million shares per day over the past 30 days. Fidelity National Information Services has a market cap of $16.8 billion and is part of the technology sector and computer software & services industry. Shares are up 10.77% year-to-date as of the close of trading on Monday.

Fidelity National Information Services, Inc. provides banking and payments technology, outsourcing, and consulting solutions worldwide. The stock currently has a dividend yield of 1.62%. The company has a P/E ratio of 30.3. Currently, there are 4 analysts who rate Fidelity National Information Services a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FIS - FREE

TheStreet Quant Ratings

rates Fidelity National Information Services as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Fidelity National Information Services Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Realpage (RP) - FREE Research Report

Seren Capital, Ltd., who is 10% Owner at Realpage, sold 39,114 shares at $21.81 on Nov. 17, 2014. Following this transaction, the 10% Owner owned 20.1 million shares meaning that the stake was reduced by 0.19% with the 39,114-share transaction.

The shares most recently traded at $21.84, up $0.03, or 0.14% since the insider transaction. Historical insider transactions for Realpage go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 16,476
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 16,476
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 148,937

The average volume for Realpage has been 452,200 shares per day over the past 30 days. Realpage has a market cap of $1.7 billion and is part of the technology sector and computer software & services industry. Shares are down 7.23% year-to-date as of the close of trading on Monday.

RealPage, Inc. provides on demand software solutions for the rental housing industry in North America. Currently, there are 2 analysts who rate Realpage a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RP - FREE

TheStreet Quant Ratings

rates Realpage as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Realpage Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Chemed (CHE) - FREE Research Report

Otoole Timothy S, who is executive vice president at Chemed, sold 5,000 shares at $106.81 on Nov. 17, 2014. Following this transaction, the executive vice president owned 34,528 shares meaning that the stake was reduced by 12.65% with the 5,000-share transaction.

The shares most recently traded at $108.60, up $1.79, or 1.65% since the insider transaction. Historical insider transactions for Chemed go as follows:

  • 4-Week # shares sold: 6,830
  • 12-Week # shares sold: 13,830
  • 24-Week # shares sold: 16,459

The average volume for Chemed has been 168,200 shares per day over the past 30 days. Chemed has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are up 40.42% year-to-date as of the close of trading on Monday.

Chemed Corporation provides hospice and palliative care services in the United States. It operates in two segments, VITAS and Roto-Rooter. The company offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The stock currently has a dividend yield of 0.82%. The company has a P/E ratio of 20.8. Currently, there is 1 analyst who rates Chemed a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHE - FREE

TheStreet Quant Ratings

rates Chemed as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, notable return on equity and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Chemed Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null